公开(公告)号：EP4461307A1

公开(公告)日：2024-11-13

申请号：EP22918327.2

申请日：2022-12-05

申请人： Chongqing Claruvis Pharmaceutical Co., Ltd.

发明人： YANG, Wu ,  GONG, Hui

IPC分类号： A61K38/48 ,  C07K14/33 ,  A61K9/08 ,  A61K47/26 ,  A61K47/18 ,  A61P25/06 ,  A61P19/08 ,  A61P27/02 ,  A61P17/00 ,  A61P21/02 ,  A61P25/00 ,  A61P29/02 ,  A61Q19/08

摘要： A botulinum toxin protein composition, comprising a botulinum toxin protein and a protein stabilizer. The protein stabilizer is selected from any one of amino acids or amino acid-like compounds, the amino acids being one or more of L-histidine, L-glycine, L-arginine, L-methionine and L-lysine, and the amino acid-like compounds comprising L-carnitine. The botulinum toxin protein composition can be used as a liquid preparation in the fields of medical treatment and beauty. The activity of the botulinum toxin protein in a liquid state can be kept stable.

公开(公告)号：EP3819304B1

公开(公告)日：2024-10-30

申请号：EP19838199.8

申请日：2019-07-16

发明人： WANG, Jiawang

IPC分类号： C07J43/00 ,  A61P21/02 ,  A61K31/58

公开(公告)号：EP4397766A1

公开(公告)日：2024-07-10

申请号：EP22864632.9

申请日：2022-08-31

申请人： Kyoto University

发明人： TOMONAGA, Keizo ,  MAKINO, Akiko ,  SAKAI, Madoka ,  KOMORIZONO, Ryo ,  URUSHITANI, Makoto ,  MORIMURA, Toshifumi ,  MINAMIYAMA, Sumio

IPC分类号： C12N15/86 ,  A61K35/76 ,  A61P21/02 ,  C12N5/10 ,  C12N7/01 ,  C07K16/40 ,  C07K16/46 ,  C12N15/13

CPC分类号： A61K35/76 ,  A61P21/02 ,  C07K16/00 ,  C07K16/40 ,  C07K16/46 ,  C12N7/00 ,  C12N5/10 ,  C12N15/86

摘要： Disclosed are a bornavirus vector comprising a nucleic acid encoding an antibody or antibody fragment capable of binding to a mutant SOD1 protein, the antibody or antibody fragment comprising a heavy-chain variable region comprising a heavy-chain CDR1 consisting of an amino acid sequence GFSLNTSGMG (SEQ ID NO: 1), a heavy-chain CDR2 consisting of an amino acid sequence IWWDDDK (SEQ ID NO: 2), and a heavy-chain CDR3 consisting of an amino acid sequence ARLGYAMDY (SEQ ID NO: 3), the heavy-chain variable region optionally having 3 or fewer amino acid substitutions, and/or a light-chain variable region comprising a light-chain CDR1 consisting of an amino acid sequence QNVGGTN (SEQ ID NO: 4), a light-chain CDR2 consisting of an amino acid sequence SAS, and a light-chain CDR3 consisting of an amino acid sequence QQYYIYPYT (SEQ ID NO: 5), the light-chain variable region optionally having 3 or fewer amino acid substitutions; a recombinant virus comprising RNA encoded by the bornavirus vector; a cell infected with the recombinant virus; and a pharmaceutical composition comprising the cell.

公开(公告)号：EP4285919A1

公开(公告)日：2023-12-06

申请号：EP23177708.7

申请日：2013-04-09

申请人： Case Western Reserve University

发明人： LANG, Bradley, T. ,  CREGG, Jared M. ,  SILVER, Jerry ,  WANG, Yi-Lan

IPC分类号： A61K38/17 ,  A61K38/16 ,  A61P35/00 ,  A61K38/46 ,  A61P25/00 ,  A61P25/02 ,  A61P25/14 ,  A61P25/16 ,  A61P25/28 ,  A61P43/00 ,  A61P25/08 ,  A61P21/02

摘要： A method of inhibiting and/or reducing the activity, signaling, and/or function of leukocyte-common antigen related (LAR) family of phosphatases in a cell of a subject induced by proteoglycans includes administering to the cell a therapeutic agent that inhibits one or more of catalytic activity, signaling, and function of the LAR family phosphatases without inhibiting binding to or activation the LAR family phosphatases by the proteoglycans.

公开(公告)号：EP3509585B1

公开(公告)日：2023-11-01

申请号：EP17849385.4

申请日：2017-09-05

发明人： CHANG, Wei-wei ,  SAWYER, Kenneth I.

IPC分类号： A61K31/352 ,  A61P25/00 ,  A61K31/57 ,  A61K9/00 ,  A61K31/164 ,  A61K31/473 ,  A61K31/565 ,  A61K31/568 ,  A61K31/573 ,  A61K45/06 ,  A61P21/02 ,  A61P25/16 ,  A61P25/28 ,  A61P27/02

公开(公告)号：EP3845230B1

公开(公告)日：2023-07-12

申请号：EP19855123.6

申请日：2019-08-30

发明人： KOJIMA Ryo ,  SAKAI Toshiro ,  AZUMA Ryota ,  TANAKA Marina

IPC分类号： A61K31/519 ,  A61K9/14 ,  A61K9/20 ,  A61K9/48 ,  A61K47/32 ,  A61K47/38 ,  A61P21/02 ,  A61P25/04 ,  A61P25/08 ,  A61P25/18 ,  A61P25/28 ,  A61P29/02 ,  A61P43/00

公开(公告)号：EP4206213A1

公开(公告)日：2023-07-05

申请号：EP22206076.6

申请日：2017-07-17

申请人： Ionis Pharmaceuticals, Inc.

发明人： RIGO, Frank ,  PRAKASH, Thazha, P. ,  SETH, Punit, P.

IPC分类号： C07H21/02 ,  A61K48/00 ,  A61P21/00 ,  A61P21/02 ,  A61P25/28 ,  A61P43/00

摘要： Disclosed herein are compounds, compositions and compounds for use in modulating splicing of SMN2, said compounds consisting in oligomers comprising a modified oligonucleotide consisting of 14-25 linked nucleosides, wherein the modified oligonucleotide is complementary to an SMN2 pre-mRNA; and wherein at least one nucleoside of the modified oligonucleotide comprises a 2'-O(N-alkyl acetamide) modified sugar moiety. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of spinal muscular atrophy.

公开(公告)号：EP2990048B1

公开(公告)日：2023-03-01

申请号：EP14740411.5

申请日：2014-01-21

发明人： MORITA, Masahiko ,  KAMIMURA, Ayako

IPC分类号： A61K38/06 ,  A61K31/198 ,  A61P3/00 ,  A61P3/02 ,  A61P3/04 ,  A61P3/06 ,  A61P7/10 ,  A61P9/00 ,  A61P9/10 ,  A61P9/12 ,  A61P11/00 ,  A61P13/12 ,  A61P15/10 ,  A61P17/00 ,  A61P21/02 ,  A61P25/28 ,  A61P27/02 ,  A61P43/00

公开(公告)号：EP4003323A1

公开(公告)日：2022-06-01

申请号：EP20847638.2

申请日：2020-05-28

申请人： Saol International Research Ltd.

发明人： PENAKE, David ,  HAMM, Sharon ,  O'MAHONY, Leonard ,  DEVANE, John ,  MOHR, Wolfgang ,  WEINHEIMER, Manuel

IPC分类号： A61K31/197 ,  A61K47/32 ,  A61P21/02

公开(公告)号：EP3233922B1

公开(公告)日：2022-05-11

申请号：EP15816762.7

申请日：2015-12-18

发明人： WEBSTER, Carl, Innes ,  THOM, Albert, George ,  JERMUTUS, Lutz, U ,  HATCHER, Jonathan, P

IPC分类号： C07K16/40 ,  C07K14/00 ,  A61P9/00 ,  A61P21/02 ,  A61P25/00 ,  A61P25/02 ,  A61P35/04 ,  A61P25/14 ,  A61P25/16 ,  A61P25/28 ,  A61P29/00 ,  A61P35/00 ,  A61P25/04 ,  A61K47/68 ,  A61K39/00